Lipocine Inc. (LPCN)
Develops oral drugs for hormone disorders, depression, liver disease, and neurological conditions using a proprietary delivery technology.
$2.14+0.00%Healthcare
StockGlow Score
Leaning Bearish
BearishBullish
1 year ago-32.1%
The outlook
LPCN is trading near its 52-week lows, well below both short and long-term moving averages, suggesting downward momentum. Analyst coverage is sparse, but the average price target implies substantial upside from current levels. Overall sentiment leans bearish despite the target gap.
What’s behind the score
Price trendBelow its 50- & 200-day averages
52-week range3% of the way from its 52-week low to high
Price targetAvg target +180% vs current price
Market cap
$17.6M
52-wk high
$12.37
52-wk low
$1.81
50-day avg
$2.29
200-day avg
$4.61
Trailing P/E
—